Mpox therapeutics in the post-STOMP/PALM era.

PURPOSE OF REVIEW: This article reviews the evidence behind mpox antiviral therapies which are clinically available and/or or under clinical investigation. For much of the mpox epidemic, tecovirimat has been used compassionately but there is no evidence of its clinical efficacy.

RECENT FINDINGS: Multiple phase 3 placebo-controlled trials have failed to demonstrate clinical efficacy of tecovirimat in the treatment of mpox.

SUMMARY: This article summarizes the evidence behind current treatment recommendations including tecovirimat, brincidofovir, cidofovir, trifluridine, and VIGIV, as well as other investigational treatments.